Eli Lilly and Company

Company LLY

Last mentioned: 2d ago

Key Data

ticker
LLY
name
Eli Lilly and Company
price
785.4
change
7.85
changePct
1.01

Timeline

  1. Impurity Warning

    Lilly issues formal warning after testing reveals impurities in compounded samples.

  2. Compounding Surge

    Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.

  3. Zepbound Approval

    Tirzepatide approved for chronic weight management, exacerbating supply shortages.

  4. Mounjaro FDA Approval

    FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.

Stories mentioning Eli Lilly and Company 1

Regulation Bearish

Lilly Flags Impurities in Compounded GLP-1s, Escalating Regulatory Battle

Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.

23 sources